Legal & General America Life Insurance Fit Review for People Living With HIV

Research Snapshot

Why Legal & General America Qualified for This Study

Questions This Section Answers

• Is Legal & General America a good choice for Life Insurance for People Living With HIV?
• How many AI platforms named Legal & General America for HIV life insurance, and at what rank?

Legal & General America qualified because three of seven platforms named it during ranking discovery, and it cleared the study's two-mention minimum. It was not a consensus leader. It appeared at rank 5 on all three platforms that named it, producing an average rank of 5.0 and a final rank of 7 across the full field ^[1].

The entity's identity is more complicated than the brand name suggests. Public Banner materials state that Legal & General Group sold Legal & General America to Meiji Yasuda, and that the Banner Life family of companies was created under Meiji Yasuda in 2026 ^[3]. Independent reporting describes a $2.3 billion acquisition completed in February 2026, with Banner continuing to operate under the Banner Life name and maintaining an A+ (Superior) A.M. Best rating ^[1]. Banner Life products are distributed in 49 states and the District of Columbia; William Penn is the New York issuer, and Banner is not authorized in New York ^[4].

That ownership and branding change matters for this use case because underwriting practices under new ownership are not publicly detailed ^[1]. Buyers should confirm which legal entity will issue a policy in their state and whether quoted rates and forms are current.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for People Living With HIV

Questions This Section Answers

• Which Legal & General America plan should a buyer living with HIV ask about first?
• Does Banner Life OPTerm offer long enough level term periods for a buyer with a managed chronic condition?

Banner Life OPTerm is the product every platform pointed to for this use case. It is a level-premium term policy with a guaranteed death benefit during the selected initial term, available in 10-, 15-, 20-, 25-, 30-, 35-, and 40-year durations ^[7]. Independent reviews note that 40-year terms exceed the typical 20- to 30-year options and suit long-term obligations such as mortgages or education costs ^[10].

Public product information lists a $100,000 minimum face amount, with issue ages from 20 through 75 depending on term duration and underwriting class; longer terms carry lower maximum issue ages ^[12]. Independent reviews describe term coverage ranging from $100,000 to $10 million ^[9].

Conversion is the second relevant feature. OPTerm policies can generally be converted to an available universal life policy during the guaranteed level-premium period or until attained age 70, whichever comes first; policies issued at age 66 or older have a shorter conversion window ^[8]. Independent reviews state that conversion to universal life requires no additional underwriting and no new medical exam unless the buyer wants certain policy changes ^[15]. Banner does not sell traditional whole life; the company focuses on term (OPTerm) and universal life (LifeStep UL), so buyers who specifically need whole life must look elsewhere ^[17].

What the AI Platforms Agreed About

Questions This Section Answers

• What do AI platforms agree on about Legal & General America for HIV life insurance?
• Is Banner Life OPTerm considered a competitive term product for applicants with a managed health condition?

Agreement was limited to product mechanics and financial strength, not HIV eligibility.

All platforms that named the entity pointed to Banner Life term coverage, most often OPTerm, as the relevant product ^[20]. Platforms also agreed that Banner's underwriting is individualized and record-heavy: underwriters review medical history, exam results, physician statements, and treatment information, and accelerated underwriting may use electronic health records, recent laboratory data, or an attending physician statement instead of a paramedical exam ^[24].

Financial strength drew broad agreement. Banner Life holds an A+ (Superior) A.M. Best rating and continues operating under the Banner Life name after the Meiji Yasuda acquisition ^[26]. Legal & General America's Banner Life and William Penn units carry high financial-strength ratings from independent rating agencies ^[28].

On pricing, independent reviews describe Banner as consistently offering some of the lowest term rates in the industry, especially for Preferred Plus or Preferred classes, with underwriting that tends to be more favorable for mild health conditions ^[29]. One review reported Banner Life as cheapest in a term cost comparison at $37 per month for women and $46 per month for men, based on 40-year-old nonsmokers buying 20-year, $500,000 coverage ^[32]. Those figures describe healthy applicants, not HIV-positive applicants.

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Do Banner Life's own underwriting guides accept or decline HIV-positive applicants?
• Why do AI platforms disagree about whether Legal & General America is HIV-friendly?

The central conflict is between company-owned underwriting documents and independent broker commentary.

Company-owned and carrier-derived documents lean restrictive. A 2021 Banner underwriting update identifies HIV-positive status as requiring underwriting contact or special review ^[33]. Banner's RiseTerm underwriting guide lists HIV positive among conditions in its underwriting restrictions ^[34]. A Banner Life underwriting field guide lists "HIV positive" under "Most likely decline," and a BeyondTerm underwriting guide lists history of HIV/AIDS as a declinable condition ^[35]. Independent underwriting guides reach similar conclusions: one lists history of HIV/AIDS as declinable ^[37], another states HIV positive is most likely a decline ^[38], and a third lists HIV positive under adverse findings ^[39].

Independent broker and review sources lean permissive. One guide states that Legal & General America (Banner Life) expanded its HIV underwriting programs and has become a reliable option for applicants in Tier 2 and Tier 3 ^[40]. Another describes Banner Life as recognized as a leading provider particularly for individuals living with HIV, with a reputation for accommodating high-risk individuals ^[42]. A 2026 broker directory lists Banner Life as a carrier willing to insure HIV-positive applicants with competitive term rates for healthy, stable profiles ^[45]. A 2026 coverage guide reports Legal & General America among carriers offering fully underwritten term and permanent policies to HIV-positive applicants who meet medical criteria ^[46].

A Legal & General adviser underwriting page adds a third position: late-stage HIV is currently declined, but some HIV-positive customers may still be considered on interactive applications ^[47]. Google's research characterized the conflict as likely reflecting manual facultative reinsurance exceptions rather than a standardized program ^[35].

Fit ratings diverged accordingly: anthropic rated the entity "good," deepseek "uncertain," google, kimi, openai, and perplexity "mixed," and grok "weak." No platform produced a clearly favorable, published HIV underwriting pathway.

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What medical factors does Banner Life underwriting review for an applicant living with HIV?
• Can a buyer living with HIV use Banner Life's accelerated no-exam underwriting?

The features most relevant to this use case are underwriting process, evidence requirements, and conversion rights.

Banner states that underwriters review medical history, exam results, physician statements, treatment information, and other records, and that decisions reflect the applicant's complete risk profile ^[49]. Accelerated underwriting may use electronic health records, attending physician statements, or recent laboratory data, but eligibility depends on applicant and product factors ^[50]. Independent reviews describe the accelerated program differently by source: one says APPcelerate can approve up to $1,000,000 without a medical exam for qualifying applicants ages 20 to 50 ^[51]; another says accelerated underwriting is available up to $4 million for ages 18–60 who qualify for Preferred or Preferred Plus ^[53]. Those thresholds conflict and should be verified. Both sources indicate that significant health conditions or higher face amounts typically require a medical exam ^[54].

For HIV cases specifically, independent guidance describes a paramedical exam and 5+ years of medical records, review by medical directors and senior underwriters, and underwriting that typically takes 6–8 weeks ^[55]. General industry criteria cited in the research include a diagnosis at least 24 months prior, continuous antiretroviral therapy, documented viral suppression, a CD4 count above 500 cells/mm³, and an undetectable viral load below 200 copies/mL on at least two consecutive lab panels ^[58]. Separate industry underwriting guidance cites a current CD4 minimum of at least 350 cells/µL within six months as a common market criterion ^[60]. These are market-level figures, not confirmed Banner rules.

Banner application materials indicate HIV testing consent may be required in some states and that results can affect underwriting decisions ^[61]. Abnormal HIV antibody test results may be disclosed to persons hired by the insurer who participate in medical underwriting decisions, to affiliates requiring the result for medical underwriting purposes, and a generic nonspecific abnormality code may be reported to the Medical Information Bureau ^[62].

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Banner Life OPTerm cost per month, and what fees apply?
• What contract terms and cancellation rights apply to a Banner Life OPTerm policy?

No HIV-specific premium can be verified from public materials. Banner's published sample price of $8.58 per month applies to a 20-year-old female nonsmoker in excellent health buying $100,000 of 10-year OPTerm coverage, and is not representative of an applicant living with HIV ^[66]. Independent sample rates of $37–$46 per month describe 40-year-old nonsmokers buying 20-year, $500,000 coverage ^[67]. Google's research estimated that an HIV-positive applicant with stable vitals might pay $60 to $150 or more per month depending on table rating, versus roughly $30 per month for a healthy 35-year-old buying $500,000 — a platform-reported estimate, not a verified quote ^[68].

Known fees and contract terms are better documented. OPTerm carries a $90 annual policy fee, with published modal factors of 0.085 for monthly electronic funds transfer, 0.26 for quarterly, and 0.51 for semiannual payment applied to the applicable annual premium ^[69]. An attending physician statement fee averaging $55, with a maximum allowable of $100, may apply when additional medical records are required ^[70]. Level premiums apply during the selected initial term; afterward, premiums may increase annually until coverage expires or the policy terminates, and coverage is stated to expire at age 95 ^[69]. Two-year contestability and suicide provisions apply ^[69]. A standard free-look period set by state law allows the policy to be returned for a refund after delivery ^[71]. Accelerated death benefits, if available and used, may affect the death benefit, premiums, policy values, liens, taxes, or public-assistance eligibility ^[69].

Pricing confidence is low to moderate across platforms. Deepseek reported low confidence and noted that HIV-specific rates are not published ^[71]. Perplexity found no reliable HIV-specific premium, fee, or face-amount schedule ^[72]. Kimi noted that premiums for HIV-positive applicants typically carry substandard ratings above standard rates ^[74].

Best Suited For

Questions This Section Answers

• Who is Legal & General America best suited for among buyers living with HIV?
• Is Banner Life OPTerm a reasonable option for a buyer with stable, documented HIV treatment?

Legal & General America is best suited for applicants living with HIV who have stable, well-documented treatment and who are willing to complete full medical underwriting through an experienced independent broker. The strongest candidates have long-term antiretroviral therapy, documented viral suppression, stable CD4 counts, and no AIDS-defining conditions ^[75].

It also suits buyers who want a defined financial obligation covered with level premiums over a long horizon, given the 10- to 40-year duration menu ^[78]. Buyers who value conversion flexibility without new underwriting may find the term-to-universal-life path useful ^[80]. Buyers who want a large, highly rated carrier with claims-paying capacity may weigh the A+ rating favorably ^[82].

The practical framing from the research is that this is one carrier to test through a broker, not an established preferred option. OpenAI's assessment called it "one carrier to test through an experienced independent broker, not as a clearly best option for people living with HIV."

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Legal & General America for Life Insurance for People Living With HIV?
• Is Banner Life a poor fit for a buyer who needs guaranteed issue or fast underwriting?

Buyers who need a predictable HIV-specific acceptance pathway should look elsewhere. Public materials do not establish whether a person living with HIV will be approved, postponed, declined, or offered a particular table rating ^[84].

Applicants with a recent diagnosis under 24 months, limited treatment history, a CD4 nadir below 200, AIDS-defining conditions, or poor medication adherence face substantially tougher underwriting and may be better served by carriers with more specialized high-risk programs ^[86]. Buyers who need guaranteed issue or simplified issue should not rely on this carrier, because Banner's simplified products list HIV as a declinable condition ^[88].

Buyers who prioritize speed and high-touch communication should also weigh the documented complaints. Independent reviews describe the most common frustration as the length of underwriting, with applicants waiting weeks or months for a decision, especially when additional medical records are needed, and a second theme of difficulty reaching someone who can give a clear status update ^[90]. Working with an agent is required to complete an application, so there is no fully independent online pathway ^[95]. Buyers who need whole life coverage must use another carrier ^[96].

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to Legal & General America for a buyer living with HIV who needs published underwriting criteria?
• When should a buyer living with HIV choose guaranteed issue instead of Banner Life OPTerm?

Another option may be better in four situations.

First, when the buyer wants published HIV underwriting criteria before applying. Guardian publishes specific criteria — CD4 above 350, undetectable viral load, 2+ years on ART, and no AIDS-defining illness — while Banner's equivalent requirements are not publicly stated ^[98]. Other carriers named in the research as having more transparent guidelines include Prudential, John Hancock, and Corebridge/AIG ^[99].

Second, when the applicant has an AIDS-defining condition, a CD4 nadir below 200, or poor medication adherence. Carriers with more specialized high-risk HIV programs, such as Prudential for standard rates or Mutual of Omaha for Tier 2, may be stronger fits ^[100].

Third, when the buyer needs guaranteed issue or simplified issue coverage and accepts lower limits or higher premiums ^[102]. Fourth, when the buyer is in New York and needs a product issued by William Penn or another authorized carrier, since Banner is not authorized in New York ^[103].

Independent HIV-focused guidance recommends consulting an experienced broker rather than assuming any specific carrier's criteria, because availability and terms vary by carrier and are not guaranteed ^[105]. Buyers comparing carriers across this category can review the full life insurance for People Living With HIV consensus index before applying anywhere.

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Legal & General America before signing a contract?
• Which underwriting details must a broker confirm in writing before an HIV-positive applicant applies?

The following questions come directly from the platform research and should be answered in writing before an application is submitted.

1. Will Banner Life currently consider an applicant living with HIV for OPTerm or universal life in the applicant's state ^[106]?
2. Is HIV-positive status an automatic decline, a required underwriting referral, or potentially eligible for standard or table-rated coverage ^[106]?
3. What current criteria apply to viral load, CD4 count, antiretroviral adherence, opportunistic infections, comorbidities, recent hospitalizations, and duration of stable treatment ^[108]?
4. Will the application require an attending physician statement, HIV specialist records, laboratory results, medication history, or a paramedical exam ^[111]?
5. Does accelerated underwriting apply to applicants living with HIV, and if not, what evidence is required ^[113]?
6. What is the maximum face amount and longest term available after HIV-specific underwriting review ^[115]?
7. Which legal entity will issue the policy in the buyer's state, and are quoted rates and policy forms current after the 2026 ownership and branding changes ^[116]?
8. What are the exact conversion deadline, available permanent products, conversion pricing basis, and state-specific limitations ^[118]?
9. Are accelerated death benefits or other riders available, and what fees, exclusions, tax effects, or benefit reductions apply ^[118]?
10. Can an independent broker obtain comparable HIV-specific offers from multiple carriers before the buyer submits a formal application ^[121]?

Final AI Consensus Verdict

Legal & General America is a mixed fit for Life Insurance for People Living With HIV. Three of seven platforms named it during ranking discovery, at rank 5 on each, producing a final rank of 7. Fit ratings split across platforms: one "good," one "uncertain," four "mixed," and one "weak."

The strongest reason to consider it is Banner Life OPTerm: a fully underwritten, level-premium term product with 10- to 40-year durations, conversion rights, a $90 annual policy fee, and competitive base rates for applicants who qualify for favorable classes ^[122]. The main limitation is that no public source establishes a predictable HIV underwriting pathway. Banner's own guides list HIV-positive status as requiring special review or as a likely decline ^[125], while independent broker sources describe expanded HIV programs without publishing thresholds ^[128].

AI-platform agreement here reflects shared source material, not verified product quality. Buyers should treat this carrier as one to test through an experienced independent broker, with written confirmation of current HIV underwriting criteria before submitting a formal application.

How This Review Was Produced

This review was produced from a fixed research run dated 2026-09-22 covering seven AI platforms: anthropic, deepseek, google, grok, kimi, openai, and perplexity. Each platform was asked which life insurance carriers are generally worth considering for applicants living with HIV, and each returned a fit assessment, product identification, pricing and terms, use-case findings, and verification questions.

Legal & General America qualified for this study because three platforms named it during ranking discovery, meeting the two-mention minimum. Ranking statistics reflect only platforms that named the entity during ranking discovery; all seven platforms evaluated fit. Citations are platform-reported evidence and were not independently verified by the writer stage. The supplied URLs were collected from platform responses and were not independently validated.

Methodology Limitations

Several limitations apply to this review.

Platform-reported research dates differ from the authoritative run date. Deepseek reported a research date of 2026-06-01, while the run date is 2026-09-22; platform-reported dates are provenance metadata and do not independently prove freshness. Deepseek also ran with search disabled, so its claims require explicit verification before being described as current facts.

The deterministic identity audit found that official-site retrieval failed for one or more mentions, that one or more fetched domains were not corroborated by brand-name or site-identity metadata, and that identity used an exact-name fallback with the reported domain retained but unverified. Company-name variants were collapsed onto one canonical brand before minimum-mention qualification. The official Legal & General America page excerpt retrieved for this run contained unrelated content and was marked retrieved-not-verified, so it was not used as proof of current product identity.

Material conflicts remain unresolved. Banner's own underwriting documents lean toward decline or special review, while independent broker sources describe expanded HIV programs. Public sources do not disclose current HIV-specific eligibility, required viral-load or CD4 thresholds, treatment-adherence standards, waiting periods, or expected premium loadings. Advertised starting prices apply to exceptionally healthy illustrative applicants and are not useful estimates for this use case. Accelerated underwriting eligibility for HIV-positive applicants is unclear. The relevant company and brand identity changed with the Meiji Yasuda acquisition, and underwriting practices under new ownership are not publicly detailed.